AT-1501 190 mg Vial
Sponsors
Eledon Pharmaceuticals Inc.
Conditions
Prophylaxis of Renal Allograft Rejection
Phase 2
BESTOW: A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation
Active, not recruitingCTIS2023-503336-41-00
Start: 2023-11-29Target: 101Updated: 2025-07-22
BESTOW-EXTENSION: A Phase 2, Multicenter,
Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Tegoprubart in Kidney
Transplant Recipients
Active, not recruitingCTIS2023-503337-21-00
Start: 2025-02-28Target: 30Updated: 2025-08-12